The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.
PET – Positron Emission Tomography
bladder cancer
immunotherapy
muscle invasive bladder cancer
staging
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
05
2020
accepted:
09
09
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients' outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.
Identifiants
pubmed: 33117695
doi: 10.3389/fonc.2020.565086
pmc: PMC7574640
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
565086Informations de copyright
Copyright © 2020 Girard, Vila Reyes, Shaish, Grellier, Dercle, Salaün, Delcroix and Rouanne.
Références
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310
pubmed: 31346755
Clin Nucl Med. 2014 May;39(5):e308-12
pubmed: 24458183
BJU Int. 2014 Sep;114(3):389-95
pubmed: 24341486
Exp Ther Med. 2015 Mar;9(3):717-724
pubmed: 25667618
Urol Int. 2014;92(2):143-9
pubmed: 23941766
J Urol. 2013 May;189(5):1687-91
pubmed: 23142689
Clin Genitourin Cancer. 2014 Dec;12(6):433-9
pubmed: 24787972
Eur J Radiol. 2014 Jan;83(1):226-30
pubmed: 24144448
Eur Urol. 2012 May;61(5):1031-8
pubmed: 22196847
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Clin Nucl Med. 2020 Feb;45(2):118-122
pubmed: 31876819
Scand J Urol Nephrol. 2011 Mar;45(2):122-8
pubmed: 21231796
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Radiology. 2019 Oct;293(1):144-150
pubmed: 31407969
World J Urol. 2018 Nov;36(11):1727-1740
pubmed: 29855698
J Bone Oncol. 2015 Sep 16;4(3):92-7
pubmed: 26587375
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):224-233
pubmed: 27565154
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167
pubmed: 31760467
Clin Imaging. 2014 Sep-Oct;38(5):704-9
pubmed: 24908368
Eur Urol Focus. 2019 Jan;5(1):90-96
pubmed: 28753817
J Clin Oncol. 2010 Sep 1;28(25):3973-8
pubmed: 20679618
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50
pubmed: 31637482
J Clin Oncol. 2009 Sep 10;27(26):4314-20
pubmed: 19652070
Eur Radiol Exp. 2020 Jan 3;4(1):2
pubmed: 31900689
Radiol Oncol. 2020 Jul 29;54(3):285-294
pubmed: 32726293
Eur Urol. 2010 Apr;57(4):641-7
pubmed: 19477579
J Urol. 2020 Aug;204(2):254-259
pubmed: 32134343
Eur Urol. 2020 Apr 29;:
pubmed: 32360052
Oncology. 2018;95(1):31-38
pubmed: 29847834
BMC Urol. 2015 Aug 21;15:87
pubmed: 26294219
World J Surg Oncol. 2015 Sep 17;13:276
pubmed: 26376852
Int Braz J Urol. 2016 Mar-Apr;42(2):234-41
pubmed: 27256176
Clin Nucl Med. 2015 Jan;40(1):e1-5
pubmed: 25188643
Eur Radiol. 2020 Jun 29;:
pubmed: 32601949
Cancers (Basel). 2019 May 20;11(5):
pubmed: 31137599
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
Exp Cell Res. 2016 Feb 1;341(1):77-83
pubmed: 26808412
Indian J Radiol Imaging. 2010 Feb;20(1):13-9
pubmed: 20351986
Mol Imaging Biol. 2012 Apr;14(2):245-51
pubmed: 21491174
World J Urol. 2016 Sep;34(9):1229-37
pubmed: 26847182
Eur Urol. 2019 Oct;76(4):524-532
pubmed: 31362898
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12288-12294
pubmed: 32430334
Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):386-93
pubmed: 23179944
Eur J Radiol. 2012 Dec;81(12):4131-7
pubmed: 22858427
BJU Int. 2013 Oct;112(6):729-34
pubmed: 23790129
Cancer Imaging. 2018 Aug 2;18(1):25
pubmed: 30068379
Q J Nucl Med Mol Imaging. 2019 Sep;63(3):284-291
pubmed: 28358186
J Am Coll Radiol. 2018 May;15(5S):S150-S159
pubmed: 29724418
World J Urol. 2018 Nov;36(11):1703-1709
pubmed: 29549485
J Nucl Med. 2020 Sep;61(9):1404-1405
pubmed: 32086243
Clin Nucl Med. 2017 Jan;42(1):e8-e15
pubmed: 27775939
Eur Urol. 2020 Feb;77(2):223-250
pubmed: 31753752
Urol Int. 2014;93(2):207-13
pubmed: 25012094
Cancer Res Treat. 2015 Oct;47(4):834-43
pubmed: 25687863
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1212-1213
pubmed: 30824964
Clin Nucl Med. 2012 Apr;37(4):366-8
pubmed: 22391706
AJR Am J Roentgenol. 2018 Mar;210(3):W95-W109
pubmed: 29381380
Acad Radiol. 2019 Sep;26(9):1137-1145
pubmed: 30424999
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Ann Surg Oncol. 2015 Sep;22(9):3150-6
pubmed: 25634779
Eur Radiol. 2020 Sep;30(9):4816-4827
pubmed: 32318846
AJR Am J Roentgenol. 2019 Feb;212(2):238-244
pubmed: 30540209
J Nucl Med Technol. 2018 Sep;46(3):268-273
pubmed: 29599404
Turk J Urol. 2019 Nov 01;45(6):423-430
pubmed: 31603416
J Nucl Med. 2018 Jan;59(1):15-24
pubmed: 28596157
Br J Radiol. 2017 Apr;90(1072):20160787
pubmed: 28256904
Clin Nucl Med. 2015 Feb;40(2):e124-8
pubmed: 25247272
Ann Nucl Med. 2018 Oct;32(8):561-567
pubmed: 30014439
Clin Genitourin Cancer. 2018 Oct;16(5):360-364
pubmed: 30001845
Scand J Urol. 2017 Aug;51(4):308-313
pubmed: 28532260
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):848-854
pubmed: 30627815
Eur Radiol. 2019 Aug;29(8):4286-4293
pubmed: 30666449
Nucl Med Commun. 2012 Nov;33(11):1195-201
pubmed: 22781846
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053
pubmed: 30181416
EBioMedicine. 2018 Aug;34:76-84
pubmed: 30078735
Clin Genitourin Cancer. 2017 Jun;15(3):e387-e395
pubmed: 27601364
Eur J Nucl Med Mol Imaging. 2020 Jul 31;:
pubmed: 32737518
Ann Nucl Med. 2012 Aug;26(7):571-7
pubmed: 22763630
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Urol. 2018 Feb;15(2):112-124
pubmed: 29205200
Int J Urol. 2012 Jul;19(7):639-44
pubmed: 22452420
Eur J Nucl Med Mol Imaging. 2020 May 25;:
pubmed: 32451603
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1391-1392
pubmed: 30888476
Eur J Cancer. 2018 Jun;96:91-104
pubmed: 29698933
Int J Urol. 2013 Aug;20(8):788-96
pubmed: 23279605
J Cancer Res Clin Oncol. 2016 Jan;142(1):187-94
pubmed: 26208817
Urology. 2014 Feb;83(2):393-8
pubmed: 24468513
Int Urol Nephrol. 2017 Sep;49(9):1585-1591
pubmed: 28674853
Eur J Surg Oncol. 2014 Dec;40(12):1724-30
pubmed: 25242381
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157
pubmed: 31754795
Clin Nucl Med. 2017 Oct;42(10):749-755
pubmed: 28759520
Clin Genitourin Cancer. 2020 Oct;18(5):378-386.e1
pubmed: 32147364
J Urol. 2011 Aug;186(2):436-41
pubmed: 21679983
Rev Esp Med Nucl Imagen Mol. 2013 Jul-Aug;32(4):214-21
pubmed: 23218514
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2301-2312
pubmed: 32206839
Clin Genitourin Cancer. 2017 Jul 26;:
pubmed: 28826932